Intech Investment Management LLC Purchases Shares of 16,292 Compass Therapeutics, Inc. (NASDAQ:CMPX)

Intech Investment Management LLC acquired a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 16,292 shares of the company’s stock, valued at approximately $30,000.

Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Compass Therapeutics by 1.7% during the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after purchasing an additional 71,008 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Compass Therapeutics by 12.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock worth $284,000 after acquiring an additional 31,433 shares during the period. Panagora Asset Management Inc. acquired a new position in shares of Compass Therapeutics during the 2nd quarter worth approximately $68,000. Rhumbline Advisers raised its stake in Compass Therapeutics by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after acquiring an additional 12,315 shares during the period. Finally, Ground Swell Capital LLC acquired a new stake in Compass Therapeutics during the 2nd quarter valued at $124,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on CMPX shares. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $5.00 to $4.00 in a report on Friday, November 15th. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Monday, November 11th. Finally, LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Monday, September 16th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $6.75.

Compass Therapeutics Trading Down 0.6 %

CMPX stock opened at $1.65 on Tuesday. The firm has a market cap of $227.02 million, a PE ratio of -4.46 and a beta of 0.89. The stock has a 50-day moving average price of $1.71 and a 200-day moving average price of $1.41. Compass Therapeutics, Inc. has a 1-year low of $0.77 and a 1-year high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. On average, analysts forecast that Compass Therapeutics, Inc. will post -0.35 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.